Filing Details
- Accession Number:
- 0001209191-20-039086
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-06-26 16:33:25
- Reporting Period:
- 2020-06-24
- Accepted Time:
- 2020-06-26 16:33:25
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1674416 | Crispr Therapeutics Ag | CRSP | Biological Products, (No Disgnostic Substances) (2836) | 473173478 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1762583 | Otto Lawrence Klein | C/O Crispr Therapeutics, Inc. 610 Main Street Cambridge MA 02139 | Cbo & Coo | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Shares | Acquisiton | 2020-06-24 | 38,666 | $5.86 | 58,666 | No | 4 | M | Direct | |
| Common Shares | Disposition | 2020-06-24 | 15,966 | $75.93 | 42,700 | No | 4 | S | Direct | |
| Common Shares | Disposition | 2020-06-24 | 22,700 | $76.50 | 20,000 | No | 4 | S | Direct | |
| Common Shares | Acquisiton | 2020-06-24 | 26,422 | $12.57 | 46,422 | No | 4 | M | Direct | |
| Common Shares | Disposition | 2020-06-24 | 6,600 | $74.90 | 39,822 | No | 4 | S | Direct | |
| Common Shares | Disposition | 2020-06-24 | 3,934 | $75.94 | 35,888 | No | 4 | S | Direct | |
| Common Shares | Disposition | 2020-06-24 | 800 | $76.50 | 35,088 | No | 4 | S | Direct | |
| Common Shares | Disposition | 2020-06-24 | 12,175 | $75.32 | 22,913 | No | 4 | S | Direct | |
| Common Shares | Disposition | 2020-06-24 | 2,913 | $76.26 | 20,000 | No | 4 | S | Direct | |
| Common Shares | Acquisiton | 2020-06-25 | 4,912 | $12.57 | 24,912 | No | 4 | M | Direct | |
| Common Shares | Disposition | 2020-06-25 | 4,912 | $75.18 | 20,000 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Shares | Stock Option (Right to Buy) | Disposition | 2020-06-24 | 38,666 | $0.00 | 38,666 | $5.86 |
| Common Shares | Stock Option (Right to Buy) | Disposition | 2020-06-24 | 26,422 | $0.00 | 26,422 | $12.57 |
| Common Shares | Stock Option (Right to Buy) | Disposition | 2020-06-25 | 4,912 | $0.00 | 4,912 | $12.57 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | 2026-03-01 | No | 4 | M | Direct | |
| 13,578 | 2026-07-14 | No | 4 | M | Direct | |
| 8,666 | 2026-07-14 | No | 4 | M | Direct |
Footnotes
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.32 to $76.31, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $76.32 to $76.73, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $74.40 to $75.36, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.40 to $76.39, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $76.45 to $76.62, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.00 to $75.95, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $76.03 to $76.62, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.00 to $75.6850, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- The Reporting Person was granted an option to purchase 106,666 shares on March 2, 2016. 43,000 of such options were previously exercised, and the shares underlying those options were sold. 25% of this option became vested and fully exercisable on February 1, 2017, and the remaining 75% of the shares shall vest in 36 equal monthly installments on the first day of each month thereafter.
- 100% of the shares shall vest in 48 equal monthly installments on the thirty-first day of each month, with the first vesting event on October 31, 2016.
Billionaire Hedge Funds
